Drug-induced liver damage in patients after cytostatic therapy for breast cancer: possibilities of correction

Hospodarsky I.Ya.,Prokopchuk O.V.

Головна
Публікації
Drug-induced liver damage in patients after cytostatic therapy for breast cancer: possibilities of correction

3 серпня 2022

1272

Ключові слова :

drug-induced liver damage,

Ліводінол®

Спеціальності :

Oncology, Hematology

Резюме

One of the most typical and widespread variants of the toxic effect of drugs on the body in general and on the liver in particular is the use of anticancer drugs. However, there is currently no standard treatment strategy for such lesions.

Aim: to investigate the effectiveness and safety of using of the Livodinol^® complex in drug-induced hepatitis induced by cytostatic therapy for breast cancer.

Object and research methods. 38 patients who received 4–6 courses of polychemotherapy after radical surgical interventions for breast cancer were examined. Patients of the 1st group (n=19) received standard detoxification therapy, patients of the 2nd group (n=19) additionally received the drug levodinol for 1 month.

Results. The use of Livodinol^® made it possible to significantly reduce the severity of subjective manifestations (pain, dyspeptic and asthenic syndromes) and clinical symptoms (increased liver size, scleral and skin icterus) of drug-induced hepatitis, as well as to significantly accelerate the normalization of biochemical indicators of liver function. The use of Livodinol^® was not accompanied by side effects in any of the patients. No toxic or allergic manifestations were noted.

Conclusion. The data obtained allow us to recommend the use of Livodinol^® for 1 month in the case of drug-induced hepatitis, in particular, induced by the use of anticancer therapy.

References

1. Björnsson E.S. (2016) Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int. J. Mol. Sci., 17(2): 224.
2. Lee W.M. (2003) Drug-induced hepatotoxicity. N. Engl. J. Med., 349(5): 474–485.
3. Iasella C.J., Johnson H.J., Dunn M.A. (2017) Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic). Clin. Liver Dis., 21(1): 73–87.
4. Shehu A.I., Ma X., Venkataramanan R. (2017) Mechanisms of Drug-Induced Hepatotoxicity. Clin. Liver Dis., 21(1): 35–54.
5. Xu Y., Yao H., Wang Q. et al. (2018) Aquaporin-3 Attenuates Oxidative Stress-Induced Nucleus Pulposus Cell Apoptosis Through Regulating the P38 MAPK Pathway. Cell Physiol. Biochem., 50: 1687–1697.
6. Wang R., Deng D., Shao N. et al. (2018) Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma. OncoTargets Ther., 11: 1183–1192.
7. Pessayre D., Mansouri A., Berson A., Fromenty B. (2009) Mitochondrial Involvement in Drug-Induced Liver Injury. Adverse Drug Reactions, pp. 311–365.
8. Mihajlovic M., Vinken M. (2022) Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods. Int. J. Mol. Sci., 23(6): 3315.
9. Prasanna P.L., Renu K., Gopalakrishnan A.V. (2020) New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci., 250: 117599.
10. Nam J., Son S., Ochyl L.J. et al. (2018) Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat. Commun., 9: 1074.
11. Roychoudhury S., Kumar A., Bhatkar D., Sharma N.K. (2020) Molecular avenues in targeted doxorubicin cancer therapy. Future Oncol., 16: 687–700.
12. Braicu C., Buse M., Busuioc C. et al. (2019) A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers, 11: 1618.
13. Pfitzer L., Moser C., Gegenfurtner F. et al. (2019) Targeting actin inhibits repair of doxorubicin-induced DNA damage: A novel therapeutic approach for combination therapy. Cell Death Dis., 10: 302.
14. Songbo M., Lang H., Xinyong C. et al. (2019) Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol. Lett., 307: 41–48.
15. Mansouri E., Jangaran A., Ashtari A. (2017) Protective effect of pravastatin on doxorubicin-induced hepatotoxicity. Bratisl. Lek. Listy, 118: 273–277.
16. Lamas D.J.M., Nicoud M.B., Sterle H.A. et al. (2015) Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell Death Discov., 1: 15059.
17. AlAsmari A.F., Alharbi M., Alqahtani F. et al. (2021) Diosmin Alleviates Doxorubicin-Induced Liver Injury via Modulation of Oxidative Stress-Mediated Hepatic Inflammation and Apoptosis via NfkB and MAPK Pathway: A Preclinical Study. Antioxidants (Basel), 10(12): 1998. doi: 10.3390/antiox10121998.
18. Oliva J., Zhong J., Buslon V.S., French S.W. (2012) The effect of SAMe and betaine on Hepa 1-6, C34 and E47 liver cell survival in vitro. Exp. Mol. Pathol., 92(1): 126–130.
19. Chen Y., Dong H., Thompson D.C., Shertzer H.G. (2013) Glutathione defense mechanism in liver injury: insights from animal models. Food Chem. Toxicol., 60: 38–44.
20. Смоланка І.І., Скляр С.Ю., Іванкова О.М., Костриба О.І. (2013) Ефективність неоад’ювантної поліхіміотерапії у хворих на рак грудної залози. Лікувальний патоморфоз. Клінічна онкологія, 2(10): 63–68.